Axsome Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $80.135
- Today's High:
- $82.39
- Open Price:
- $80.38
- 52W Low:
- $20.63
- 52W High:
- $82.85
- Prev. Close:
- $80.6
- Volume:
- 420994
Company Statistics
- Market Cap.:
- $3.26 billion
- Book Value:
- 2.568
- Revenue TTM:
- $144.61 million
- Operating Margin TTM:
- -98.99%
- Gross Profit TTM:
- $45.94 million
- Profit Margin:
- -109.75%
- Return on Assets TTM:
- -37.45%
- Return on Equity TTM:
- -250.92%
Company Profile
Axsome Therapeutics Inc had its IPO on 2015-11-19 under the ticker symbol AXSM.
The company operates in the Healthcare sector and Biotechnology industry. Axsome Therapeutics Inc has a staff strength of 393 employees.
Stock update
Shares of Axsome Therapeutics Inc opened at $80.38 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $80.14 - $82.39, and closed at $82.21.
This is a +2% increase from the previous day's closing price.
A total volume of 420,994 shares were traded at the close of the day’s session.
In the last one week, shares of Axsome Therapeutics Inc have increased by +0.64%.
Axsome Therapeutics Inc's Key Ratios
Axsome Therapeutics Inc has a market cap of $3.26 billion, indicating a price to book ratio of 20.6587 and a price to sales ratio of 134.7595.
In the last 12-months Axsome Therapeutics Inc’s revenue was $144.61 million with a gross profit of $45.94 million and an EBITDA of $-141259392. The EBITDA ratio measures Axsome Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Axsome Therapeutics Inc’s operating margin was -98.99% while its return on assets stood at -37.45% with a return of equity of -250.92%.
In Q1, Axsome Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Axsome Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-3.85 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Axsome Therapeutics Inc’s profitability.
Axsome Therapeutics Inc stock is trading at a EV to sales ratio of 121.4737 and a EV to EBITDA ratio of -20.9755. Its price to sales ratio in the trailing 12-months stood at 134.7595.
Axsome Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $389.18 million
- Total Liabilities
- $100.65 million
- Operating Cash Flow
- $-71000.00
- Capital Expenditure
- $71000
- Dividend Payout Ratio
- 0%
Axsome Therapeutics Inc ended 2025 with $389.18 million in total assets and $0 in total liabilities. Its intangible assets were valued at $389.18 million while shareholder equity stood at $111.81 million.
Axsome Therapeutics Inc ended 2025 with $0 in deferred long-term liabilities, $100.65 million in other current liabilities, 4000.00 in common stock, $-607551000.00 in retained earnings and $10.31 million in goodwill. Its cash balance stood at $246.52 million and cash and short-term investments were $246.52 million. The company’s total short-term debt was $108,000 while long-term debt stood at $147.62 million.
Axsome Therapeutics Inc’s total current assets stands at $304.45 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $44.79 million compared to accounts payable of $35.77 million and inventory worth $7.94 million.
In 2025, Axsome Therapeutics Inc's operating cash flow was $-71000.00 while its capital expenditure stood at $71000.
Comparatively, Axsome Therapeutics Inc paid $0 in dividends in 2025.
Other key metrics
- Current Trading Price
- $82.21
- 52-Week High
- $82.85
- 52-Week Low
- $20.63
- Analyst Target Price
- $111.08
Axsome Therapeutics Inc stock is currently trading at $82.21 per share. It touched a 52-week high of $82.85 and a 52-week low of $82.85. Analysts tracking the stock have a 12-month average target price of $111.08.
Its 50-day moving average was $75.06 and 200-day moving average was $71.68 The short ratio stood at 9.42 indicating a short percent outstanding of 0%.
Around 1849.3% of the company’s stock are held by insiders while 7077.1% are held by institutions.
Frequently Asked Questions About Axsome Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer’s disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that is in Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial of for treating attention-deficit/hyperactivity disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.